Last reviewed · How we verify
NCT07024524
Perceptual Evaluation and Rehabilitation System Development for Congenital Hearing Loss
NA trial testing Rehabilitation training in Congenital Hearing Loss in 210 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 210 |
| Start date | 4 July 2025 |
| Primary completion | 1 January 2028 |
| Estimated completion | 5 May 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Rehabilitation training
Conditions studied
- Congenital Hearing Loss — all drugs for Congenital Hearing Loss →
- Gene Therapy — all drugs for Gene Therapy →
- Speech Perception — all drugs for Speech Perception →
- Rehabilitation — all drugs for Rehabilitation →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
Adults 1 to 35, any sex, with Congenital Hearing Loss or Gene Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to establish a novel multimodal evaluation and precision rehabilitation system for patients with congenital hearing loss who have received hearing aids, cochlear implantation, or emerging gene therapy. The proposed system will integrate age-stratified difficulty levels, combined with a gamified interaction platform or software designed to assess and train three core perceptual domains: auditory speech perception, music perception, and spatial hearing capabilities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07024524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rehabilitation training
Trials testing the same drug.
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT06199375 — Effect of Modified Mirror Therapy in Patients With Upper Limb Hemiparesis After Stroke · NA · terminated
- NCT06329934 — Refined Nursing in Rehabilitation Training · NA · completed
Other recruiting trials for Congenital Hearing Loss
Currently open trials in the same condition.
- NCT05775367 — Cochlear Implants in Young Children With SSD · NA · recruiting
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07024524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07024524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing